These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

837 related items for PubMed ID: 16298594

  • 1. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E, Delucchi MA, Cano F, Valdebenito S, Castillo MC, Villegas R.
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [Abstract] [Full Text] [Related]

  • 2. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
    Rodrigo E, Ruiz JC, Angeles de Cos M, Ruiz J, Gago M, Piñera C, Sánchez B, González-Cotorruelo J, Gómez-Alamillo C, Arias M.
    Transplant Proc; 2009 Oct; 41(6):2328-31. PubMed ID: 19715910
    [Abstract] [Full Text] [Related]

  • 3. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP, Canter C, Shepherd R, Lassa-Claxton S, Nadler M.
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [Abstract] [Full Text] [Related]

  • 4. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
    Caforio AL, Tona F, Piaserico S, Gambino A, Feltrin G, Fortina AB, Angelini A, Alaibac M, Bontorin M, Calzolari D, Peserico A, Thiene G, Iliceto S, Gerosa G.
    Transpl Int; 2005 Jan; 18(1):116-24. PubMed ID: 15612993
    [Abstract] [Full Text] [Related]

  • 5. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 6. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    John U, Ullrich S, Roskos M, Misselwitz J.
    Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
    [Abstract] [Full Text] [Related]

  • 7. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
    Hangler HB, Ruttmann E, Geltner C, Bucher B, Nagiller J, Laufer G, Mueller LC.
    Clin Transplant; 2008 Apr; 22(1):35-40. PubMed ID: 18217903
    [Abstract] [Full Text] [Related]

  • 8. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M, Chadban S, Cole E, Midtvedt K, Thervet E, Prestele H, Keown P.
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [Abstract] [Full Text] [Related]

  • 9. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M, Armstrong VW, Streit F, Weber L, Tönshoff B.
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [Abstract] [Full Text] [Related]

  • 10. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F, Gonzalez L, Trull AK.
    J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
    [Abstract] [Full Text] [Related]

  • 11. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients.
    Strong DK, Lai A, Primmett D, White CT, Lirenman DS, Carter JE, Hurley RM, Virji M, Ensom MH.
    Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411
    [Abstract] [Full Text] [Related]

  • 12. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring.
    Ventura E, Bonardet A, Pageaux GP, Mourad G, Cristol JP.
    Transplant Proc; 2009 Mar; 41(2):707-9. PubMed ID: 19328963
    [Abstract] [Full Text] [Related]

  • 13. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
    Bunnag S, Vareesangthip K, Ong-ajyooth L.
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476
    [Abstract] [Full Text] [Related]

  • 14. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Hübler M, Abd El Rahman MY, Miera O, Ewert P, Weng Y, Wei H, Krüdewagen B, Hetzer R, Berger F.
    J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
    [Abstract] [Full Text] [Related]

  • 15. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
    Midtvedt K, Fauchald P, Bergan S, Høieggen A, Hallan S, Svarstad E, Bergrem H, Eriksen BO, Pfeffer PF, Dalen I, Leivestad T.
    Transplantation; 2003 Oct 27; 76(8):1236-8. PubMed ID: 14578761
    [Abstract] [Full Text] [Related]

  • 16. Cyclosporine dose reduction in stable renal transplant patients with high C2 level: simplified method of single C2 measurement and individualization of C0 target.
    Higgins RM, Kanji H, Hernon M, Harrison P, Lam FT, Kashi SH.
    Transpl Int; 2005 Jul 27; 18(7):806-10. PubMed ID: 15948859
    [Abstract] [Full Text] [Related]

  • 17. Rationale for monitoring cyclosporine concentration at 2 hours after administration in infants posttransplantation.
    Furlan V, Lykavieris P, Maubert MA, Habes D, Debray D.
    Transplant Proc; 2009 Oct 27; 41(8):3333-4. PubMed ID: 19857744
    [Abstract] [Full Text] [Related]

  • 18. Preliminary evaluation of a new chemiluminescence assay (Liaison Cyclosporine; DiaSorin Laboratories) allowing both C0 and C2 cyclosporine levels determination: comparison with RIA method.
    Olejnik Y, Elaerts S, Bonardet A, Chong G, Mourad G, Cristol JP, Dupuy AM.
    Transplant Proc; 2005 Oct 27; 37(1):172-4. PubMed ID: 15808584
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M, Crespo M, Millán O, Serón D, Torregrosa V, Jiménez O, Moreso F, Martorell J, Grinyo JM, Oppenheimer F.
    Transplant Proc; 2007 Sep 27; 39(7):2160-2. PubMed ID: 17889124
    [Abstract] [Full Text] [Related]

  • 20. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
    Takatsuki M, Chen CL, Chen YS, Wang CC, Lin CC, Yang CH, Yong CC, Liu YW.
    Clin Transplant; 2004 Dec 27; 18(6):694-9. PubMed ID: 15516246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.